Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 7x per week according to the following cadence:
Mondays: Stocks
Tuesdays: Biotech
Wednesdays: Podcast
Thursdays: Markets
Fridays: News
Saturdays: Podcast
Sundays: Strategy
We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.
SUBSCRIBE TO THE PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
This week’s episode breaks down Outset Medical ($OM) ahead of its Q3 2026 earnings catalyst, focusing on whether the company can finally convert its large Tablo installed base and HCA fleet refresh into the second-half revenue acceleration embedded in guidance. We walk through the bull and bear cases around acute-console demand, consumable pull-through, recurring revenue and gross-margin durability, while asking whether hospital adoption is translating into real utilization and attractive economics or simply a larger installed footprint. We also examine the competitive threat from entrenched outsourced dialysis workflows, the importance of HCA as both a validation signal and a potential source of timing risk, Outset’s cash runway and path toward breakeven, short-interest dynamics, and the asymmetric catalyst setup that could produce a sharp re-rating on clean execution or a much more severe downside reset if the expected inflection is delayed again.
📣🎙️ TODAY’S PODCAST:
[ 01:04 ] Outset Medical execution test
[ 03:12 ] Revenue guidance math
[ 05:30 ] HCA fleet refresh
[ 08:50 ] Recurring revenue economics
[ 10:51 ] Outsourced dialysis competition
[ 13:09 ] Quality of Q3 revenue
[ 14:50 ] Cash runway versus sufficiency
[ 17:12 ] Options market asymmetry
[ 20:06 ] Q3 catalyst scenarios
[ 21:40 ] Economics scale financially
Thanks for reading BowTiedBiotech! Please help us grow our audience - sharing is caring!
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.